Loading...
Metabolic Capacity Expansion And Peptide Outsourcing Shifts Will Face Headwinds Yet Ultimately Support Upside
n/a
n/a
AnalystLowTarget's Fair Value
n/a
1Y
117.1%7D
6.2%1Y
117.1%7D
6.2%You can edit this narrative until Dec 17 1:05 PM. Then, changes will post as Updates.
Author's Valuation
CHF 28.879.6% overvalued intrinsic discount
AnalystLowTarget Fair Value